Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
St. Luke's Hospital
2342
mi
from 98109
Bethlehem, PA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
St. Luke's Hospital
2342
mi
from 98109
Bethlehem, PA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Magee-Womens Hospital of UPMC
2134
mi
from 98109
Pittsburgh, PA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Magee-Womens Hospital of UPMC
2134
mi
from 98109
Pittsburgh, PA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Western Pennsylvania Hospital
2134
mi
from 98109
Pittsburgh, PA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Western Pennsylvania Hospital
2134
mi
from 98109
Pittsburgh, PA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Chattanooga's Program in Women's Oncology
2083
mi
from 98109
Chattanooga, TN
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Chattanooga's Program in Women's Oncology
2083
mi
from 98109
Chattanooga, TN
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Vanderbilt University Medical Center
1971
mi
from 98109
Nashville, TN
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Texas Oncology, PA
1681
mi
from 98109
Dallas, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Texas Oncology, PA
1681
mi
from 98109
Dallas, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Texas Oncology Wichita Falls Texoma
1556
mi
from 98109
Wichita, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Texas Oncology Wichita Falls Texoma
1556
mi
from 98109
Wichita, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Texas Oncology - Baylor Charles A. Simmons Cancer Center
1681
mi
from 98109
Dallas, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Texas Oncology - Baylor Charles A. Simmons Cancer Center
1681
mi
from 98109
Dallas, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
International Beneficence Clinical Research, LLC
1994
mi
from 98109
Harlingen, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
International Beneficence Clinical Research, LLC
1994
mi
from 98109
Harlingen, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
University of Texas Health Science Center at Houston
1884
mi
from 98109
Houston, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
University of Texas Health Science Center at Houston
1884
mi
from 98109
Houston, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
South Texas Oncology and Hematology
1780
mi
from 98109
San Antonio, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
South Texas Oncology and Hematology
1780
mi
from 98109
San Antonio, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Scott and White Hosptial, Texas A&M University
1740
mi
from 98109
Temple, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Scott and White Hosptial, Texas A&M University
1740
mi
from 98109
Temple, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
US Oncology Research
1556
mi
from 98109
Wichita Falls, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
US Oncology Research
1556
mi
from 98109
Wichita Falls, TX
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Northern Utah Associates
678
mi
from 98109
Ogden, UT
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Northern Utah Associates
678
mi
from 98109
Ogden, UT
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Utah Cancer Specialists
705
mi
from 98109
Salt Lake City, UT
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Utah Cancer Specialists
705
mi
from 98109
Salt Lake City, UT
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Northern Virginia Pelvic Surgery Associates
2316
mi
from 98109
Annandale, VA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Northern Virginia Pelvic Surgery Associates
2316
mi
from 98109
Annandale, VA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Peninsula Cancer Institute
2415
mi
from 98109
Newport News, VA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Peninsula Cancer Institute
2415
mi
from 98109
Newport News, VA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Cancer Care Northwest - Spokane South
229
mi
from 98109
Spokane, WA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Cancer Care Northwest - Spokane South
229
mi
from 98109
Spokane, WA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Northwest Cancer Specialists
138
mi
from 98109
Vancouver, WA
Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly MORAb-003 in Combination With Carboplatin and Taxane in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse
Status: Archived
Updated: 1/1/1970
Northwest Cancer Specialists
138
mi
from 98109
Vancouver, WA
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer
Status: Archived
Providence Medical Center
145
mi
from 98109
Portland, OR
Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer
A Pilot Study of Autologous Tumor DRibble Vaccine With Docetaxel in Stage IIIB and IV Non-Small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Providence Medical Center
145
mi
from 98109
Portland, OR
Computer Program to Find and Diagnose Cancer or Other Diseases Using Radiologic Images
Development and Evaluation of Techniques for Computer Aided Detection and Diagnosis From Radiologic Images
Status: Archived
National Cancer Institute (NCI)
2315
mi
from 98109
Bethesda, MD
Computer Program to Find and Diagnose Cancer or Other Diseases Using Radiologic Images
Development and Evaluation of Techniques for Computer Aided Detection and Diagnosis From Radiologic Images
Status: Archived
Updated: 1/1/1970
National Cancer Institute (NCI)
2315
mi
from 98109
Bethesda, MD
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Horizon Oncology Center
1816
mi
from 98109
Lafayette, IN
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Updated: 1/1/1970
Horizon Oncology Center
1816
mi
from 98109
Lafayette, IN
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Greenebaum Cancer Center - University of Maryland
2327
mi
from 98109
Baltimore, MD
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Updated: 1/1/1970
Greenebaum Cancer Center - University of Maryland
2327
mi
from 98109
Baltimore, MD
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Center for Cancer & Blood Disorders
2314
mi
from 98109
Bethesda, MD
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Updated: 1/1/1970
Center for Cancer & Blood Disorders
2314
mi
from 98109
Bethesda, MD
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Wayne State University/Detroit Medical Center
1932
mi
from 98109
Detroit, MI
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Updated: 1/1/1970
Wayne State University/Detroit Medical Center
1932
mi
from 98109
Detroit, MI
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Great Lakes Cancer Institute - Michigan State University
1853
mi
from 98109
Lansing, MI
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Updated: 1/1/1970
Great Lakes Cancer Institute - Michigan State University
1853
mi
from 98109
Lansing, MI
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Providence Cancer Institute
1921
mi
from 98109
Southfield, MI
Study of EC0489 for the Treatment of Refractory or Metastatic Tumors
A Phase I Study of EC0489 Administered Weeks 1 and 3 of a 4-Week Cycle
Status: Archived
Updated: 1/1/1970
Providence Cancer Institute
1921
mi
from 98109
Southfield, MI
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Status: Archived
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
A Phase 1/2, Single-Arm Study To Assess The Efficacy and Safety Of 72-Hour Continuous Intravenous Dosing Of ON 01910.Na Administered Every Other Week in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Status: Archived
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Phase 2 Clinical Study of Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
2485
mi
from 98109
Boston, MA
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
A Phase I Study of Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
Status: Archived
Memorial Sloan-Kettering Cancer Center - Basking Ridge
2377
mi
from 98109
Basking Ridge, NJ
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
A Phase I Study of Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
Status: Archived
Updated: 1/1/1970
Memorial Sloan-Kettering Cancer Center - Basking Ridge
2377
mi
from 98109
Basking Ridge, NJ
Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma
A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) for Patients Failing Radiation Therapy
Status: Archived
Tufts Clinical Pharmacology Study Unit
2485
mi
from 98109
Boston, MA
Safety Study Using Photodynamic Therapy Light Therapy for Patients With Chest Wall Progression of Breast Cancer and Satellite Metastases of Melanoma
A Phase I Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) for Patients Failing Radiation Therapy
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
2485
mi
from 98109
Boston, MA
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
A Phase II Trial of Clofarabine and Cytarabine to Treat Minimal Residual Disease (MRD) in Acute Myeloid Leukemia
Status: Archived
Fred Hutchinson Cancer Research Center
0
mi
from 98109
Seattle, WA
Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease
A Phase II Trial of Clofarabine and Cytarabine to Treat Minimal Residual Disease (MRD) in Acute Myeloid Leukemia
Status: Archived
Updated: 1/1/1970
Fred Hutchinson Cancer Research Center
0
mi
from 98109
Seattle, WA
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Status: Archived
McFarland Clinic, PC
1450
mi
from 98109
Ames, IA
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
McFarland Clinic, PC
1450
mi
from 98109
Ames, IA
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Status: Archived
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Study of Pazopanib and Paclitaxel in Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Phase I/II Study of Pazopanib in Combination With Paclitaxel in First-line Treatment of Subjects With Stage IIIBwet/IV Non-small Cell Lung Cancer
Status: Archived
Updated: 1/1/1970
Medical University of South Carolina
2422
mi
from 98109
Charleston, SC
Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip
A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip.
Status: Archived
Tufts Clinical Pharmacology Study Unit
2485
mi
from 98109
Boston, MA
Photodynamic Therapy to Treat Actinic Damage in Patients With Squamous Cell Carcinoma (SCC) of the Lip
A Clinical Trial of ALA Photodynamic Therapy for Treatment of Actinic Cheilitis in Patients With Squamous Cell Carcinoma of the Lip.
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
2485
mi
from 98109
Boston, MA
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary
Status: Archived
Washington University
1717
mi
from 98109
St. Louis, MO
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary
Status: Archived
Updated: 1/1/1970
Washington University
1717
mi
from 98109
St. Louis, MO
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary
Status: Archived
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
GTX Regimen for Biliary Cancers
Phase II Study of the Gemzar, Taxotere and Xeloda Regimen (GTX) for Inoperable or Metastatic Adenocarcinoma of the Biliary System
Status: Archived
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
GTX Regimen for Biliary Cancers
Phase II Study of the Gemzar, Taxotere and Xeloda Regimen (GTX) for Inoperable or Metastatic Adenocarcinoma of the Biliary System
Status: Archived
Updated: 1/1/1970
Columbia Presbyterian Med Ctr
2400
mi
from 98109
New York, NY
A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors
A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors
Status: Archived
Washington University
1717
mi
from 98109
St. Louis, MO
A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors
A Phase I Study of Bi-Weekly rBBX-01 in Patients With Solid Tumors
Status: Archived
Updated: 1/1/1970
Washington University
1717
mi
from 98109
St. Louis, MO
Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study
Status: Archived
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
1733
mi
from 98109
Chicago, IL
Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study
Status: Archived
Updated: 1/1/1970
Robert H. Lurie Comprehensive Cancer Center at Northwestern University
1733
mi
from 98109
Chicago, IL
Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study
Status: Archived
University of Chicago
1737
mi
from 98109
Chicago, IL
Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps
Vitamin D Intervention For Colon Cancer Prevention In African-Americans-A Pilot Study
Status: Archived
Updated: 1/1/1970
University of Chicago
1737
mi
from 98109
Chicago, IL
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1065
mi
from 98109
San Diego, CA
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2099
mi
from 98109
New Orleans, LA
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Clinical Research Facility
2402
mi
from 98109
Bronx, NY
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2402
mi
from 98109
Bronx, NY
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Clinical Research Facility
2041
mi
from 98109
Akron, OH
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
2041
mi
from 98109
Akron, OH
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Clinical Research Facility
1890
mi
from 98109
Houston, TX
A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer
Phase 2, Open-label, Single-Arm, Multi Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
1890
mi
from 98109
Houston, TX
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Status: Archived
Huntsman Cancer Hospital
702
mi
from 98109
Salt Lake City, UT
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction
Status: Archived
Updated: 1/1/1970
Huntsman Cancer Hospital
702
mi
from 98109
Salt Lake City, UT
Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Archived
Providence Cancer Center at Providence Hospital
2145
mi
from 98109
Mobile, AL
Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Providence Cancer Center at Providence Hospital
2145
mi
from 98109
Mobile, AL
Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Archived
Alaska Regional Hospital Cancer Center
1429
mi
from 98109
Anchorage, AK
Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Randomized Phase II Study of Docetaxel Followed by Vandetanib (ZD6474) vs. Docetaxel Plus Vandetanib in Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
Status: Archived
Updated: 1/1/1970
Alaska Regional Hospital Cancer Center
1429
mi
from 98109
Anchorage, AK